Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker - Furumatsu, Y; Nagasawa, Y; Tomida, K; Mikami, S; Kaneko, T; Okada, N; Tsubakihara, Y; Imai, E; Shoji, T (Hypertens Res, 2008)